Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06967181 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
A Phase 1 study of Mumps, sponsored by CyanVac.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT06967181: Active Phase 1 study of Mumps, sponsored by CyanVac.
NCT06967181 is a Phase 1 study of Mumps that is active but no longer recruiting, run by CyanVac. The registered enrollment target is 60 participants, below the 2,424-participant average among 3 other Mumps trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06967181, a Phase 1 study of Mumps, is active but no longer recruiting, sponsored by CyanVac.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Primary Outcome
The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intranasal administration through 7 days post-vaccination (Day 1 through Day 8)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL CVM150
- BIOLOGICAL CVM26
Study Locations (3)
New York
- University Of Rochester Medical Center - Rochester
Ohio
- Cincinnati Children's Hospital Medical Center Vaccine Research Center - Cincinnati
South Carolina
- Coastal Carolina Research Center - North Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What the registry record for NCT06967181 still lists
NCT06967181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,424-participant average among 3 other Mumps trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Mumps appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06967181 reports a single indexed study location in New York, Ohio, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06967181 about?
NCT06967181 is a clinical study titled "A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults". The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
What is the current status of trial NCT06967181?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-05-14. Estimated completion is 2027-12.
What conditions does trial NCT06967181 study?
This clinical trial studies the following conditions: Mumps.
What interventions are being tested in trial NCT06967181?
The interventions under investigation include: Placebo (OTHER), CVM150 (BIOLOGICAL), CVM26 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06967181?
This trial is sponsored by CyanVac, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06967181 being conducted?
This trial has 3 study locations across New York, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mumps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
COMPLETED · Phase 3
-
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
COMPLETED · Phase 3
-
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI